Sublingual immunotherapy for allergic conjunctivitis: Cochrane systematic review and meta-analysis

Clinical and Experimental Allergy

Volumn 41, Issue 9, 2011, Pages 1263-1272

  Calderon, M A ^a   Penagos, M ^a   Sheikh, A ^b   Canonica, G W ^c   Durham, S R ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

Allergic; Conjunctivitis; Eye; Immunotherapy; Meta analysis; Ocular; Rhinitis; Sublingual; Symptoms

Indexed keywords

CAT EXTRACT; EYE DROPS; GRASS POLLEN EXTRACT; PLACEBO; POLLEN EXTRACT; TREE POLLEN EXTRACT; UNCLASSIFIED DRUG;

ALLERGIC CONJUNCTIVITIS; ARTICLE; CONJUNCTIVAL IMMEDIATE ALLERGEN SENSITIVITY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; EPIPHORA; EYE REDNESS; EYE SWELLING; HUMAN; META ANALYSIS; OCULAR PRURITUS; PRIORITY JOURNAL; PUBLISHING; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SENSITIVITY ANALYSIS; SUBLINGUAL IMMUNOTHERAPY; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; THERAPY EFFECT; TREATMENT OUTCOME;

ADMINISTRATION, SUBLINGUAL; ALLERGENS; CONJUNCTIVITIS, ALLERGIC; DESENSITIZATION, IMMUNOLOGIC; HUMANS; PUBLICATION BIAS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 80051770977     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2011.03835.x     Document Type: Article

References (80)

1. Berger W, Abelson MB, Gomes PJ et al. Effects of adjuvant therapy with 0.1% olopatadine hydrochloride ophthalmic solution on quality of life in patients with allergic rhinitis using systemic or nasal therapy. Ann Allergy Asthma Immunol 2005; 95:361-7.
2. Canonica GW, Bousquet J, Mullol J, Scadding GK, Virchow JC. A survey of the burden of allergic rhinitis in Europe. Allergy 2007; 62:s17-25.
3. Torkildsen GL, Gomes P, Welch D, Gopalan G, Srinivasan S. Evaluation of desloratadine on conjunctival allergen challenge-induced ocular symptoms. Clin Exp Allergy 2009; 39:1052-9.
4. Bielory L, Katelaris CH, Lightman S, Naclerio RM. Treating the ocular component of allergic rhinoconjunctivitis and related eye disorders. MedGenMed 2007; 9:35.
5. Bielory L, Mongia A. Current opinion of immunotherapy for ocular allergy. Curr Opin Allergy Clin Immunol 2002; 2:447-52.
6. Bielory L. Ocular allergy overview. Immunol Allergy Clin North Am 2008; 28:1-23.
7. Bielory L. Differential diagnoses of conjunctivitis for clinical allergist-immunologists. Ann Allergy Asthma Immunol 2007; 98:105-14.
8. Dahl R, Kapp A, Colombo G et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 118:434-40.
9. Didier A, Malling HJ, Worm M et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007; 120:1338-45.
10. Durham SR, Riis B. Grass allergen tablet immunotherapy relieves individual seasonal eye and nasal symptoms, including nasal blockage. Allergy 2007; 62:954-7.
11. Mortemousque B, Bertel F, De Casamayor J, Verin P, Colin J. House-dust mite sublingual-swallow immunotherapy in perennial conjunctivitis: a double-blind, placebo-controlled study. Clin Exp Allergy 2003; 33:464-9.
12. U.S. National Institutes of Health. Clinical trials. Available at [Accessed on December 27, 2010].
13. Australian National Health and Medical Research Council and New Zealand Health Research Council. Australian New Zealand Clinical Trials Registry. Available at [Accessed on December 27, 2010].
14. Current Controlled Trials Ltd. Current controlled trials. Available at [Accessed on 27 December 2010].
15. Dawson B, Trapp RG. Research questions about one group. In: Basic & Clinical Biostatistics, 4th edition. New York: McGraw-Hill Professional, 2004; 118-127.
16. Higgins JPT, Deeks JJ. Chapter 7: selecting studies and collecting data. In Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from .
17. Higgins JPT, Altman DG, Sterne JAC. Chapter 8: assessing risk of bias in included studies. In Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from .
18. The Cochrane Collaboration Review Manager (RevMan) [Computer program]. Version 5.0. Copenhagen: The Nordic Cochrane Centre, 2008.
19. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21:1539-58.
20. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Br Med J 2003; 327:557-60.
21. Deeks JJ, Higgins JPT, Altman DG. Chapter 9: analysing data and undertaking meta-analyses. In Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011, Available from .
22. Sutton AJ, Higgins JP. Recent developments in meta-analysis. Stat Med 2008; 27:625-50.
23. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50:1088-101.
24. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Br Med J 1997; 315:629-34.
25. Sterne JA, Egger M, Smith GD. Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. Br Med J 2001; 323:101-5.
26. Calderon MA, Penagos M, Sheikh A, Canonica GW, Durham S. Sublingual immunotherapy for treating allergic conjunctivitis. Cochrane Database of Systematic Reviews (2), art. no. CD007685.
27. André C, Perrin-Fayolle M, Grosclaude M et al. A double-blind placebo-controlled evaluation of sublingual immunotherapy with a standardized ragweed extract in patients with seasonal rhinitis. Evidence for a dose-response relationship. Int Arch Allergy Immunol 2003; 131:111-8.
28. Ariano R, Spadolini I, Panzani RC. Efficacy of sublingual specific immunotherapy in Cupressaceae allergy using an extract of Cupressus arizonica. A double blind study. Allergol Immunopathol (Madrid) 2001; 29:238-44.
29. Aydogan M, Keles S, Eifan A et al. Impact of sublingual immunotherapy on development of asthma in children with allergic rhinitis sensitised to house-dust-mite: a double blind placebo controlled study. Allergy 2007; 62:74.
30. Bowen T, Greenbaum J, Charbonneau Y et al. Canadian trial of sublingual swallow immunotherapy for ragweed rhinoconjunctivitis. Ann Allergy Asthma Immunol 2004; 93:425-30.
31. Bufe A, Ziegler-Kirbach E, Stoeckmann E et al. Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study. Allergy 2004; 59:498-504.
32. Bufe A, Eberle P, Franke-Beckmann E et al. Phase III trial with grass allergen tablet for sublingual immunotherapy in children. J Allergy Clin Immunol 2009; 123:167-73.
33. Cao LF, Lu Q, Gu HL et al. Clinical evaluation for sublingual immunotherapy of allergic asthma and atopic rhinitis with Dermatophagoides farinae drops. Zhonghua Er Ke Za Zhi 2007; 45:736-41.
34. Casanovas M, Guerra F, Moreno C, Miguel R, Marañón F, Daza JC. Double-blind, placebo-controlled clinical trial of preseasonal treatment with allergenic extracts of Olea europaea pollen administered sublingually. J Invest Allergol Clin Immunol 1994; 4:305-14.
35. Dahl R, Stender A, Rak S. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. Allergy 2006; 61:185-90.
36. de Blay F, Barnig CSUBLIM Group et al. Sublingual-swallow immunotherapy with standardized 3-grass pollen extract: a double-blind, placebo-controlled study. Ann Allergy Asthma Immunol 2007; 99:453-61.
37. Dubakiene R, Kleinjans HAJ. Effectiveness of specific sublingual IT (SLIT) with tree pollen. A placebo controlled study in 119 patients. In: XXII Congress of the EAACI. Abstract No. 785. Paris, France. 2003 (Abstract Book).
38. Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 117:802-9.
39. Feliziani V, Lattuada G, Parmiani S, Dall'Aglio PP. Safety and efficacy of sublingual rush immunotherapy with grass allergen extracts. A double blind study. Allergol Immunopathol (Madrid) 1995; 23:224-30.
40. Hirsch T, Sähn M, Leupold W. Double-blind placebo-controlled study of sublingual immunotherapy with house dust mite extract (D. pt.) in children. Pediatr Allergy Immunol 1997; 8:21-7.
41. Horak F, Stübner P, Berger UE, Marks B, Toth J, Jäger S. Immunotherapy with sublingual birch pollen extract. A short-term double-blind placebo study. J Invest Allergol Clin Immunol 1998; 8:165-71.
42. Khinchi MS, Poulsen LK, Carat F, André C, Hansen AB, Malling HJ. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study. Allergy 2004; 59:45-53.
43. La Rosa M, Ranno C, André C, Carat F, Tosca MA, Canonica GW. Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 1999; 104:425-32.
44. Moreno-Ancillo A, Moreno C, Ojeda P et al. Efficacy and quality of life with once-daily sublingual immunotherapy with grasses plus olive pollen extract without updosing. J Invest Allergol Clin Immunol 2007; 17:399-405.
45. Ott H, Sieber J, Brehler R et al. Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study. Allergy 2009; 64:179-86.
46. Palma-Carlos AG, Santos AS, Branco-Ferreira M et al. Clinical efficacy and safety of preseasonal sublingual immunotherapy with grass pollen carbamylated allergoid in rhinitic patients. A double-blind, placebo-controlled study. Allergol Immunopathol (Madrid) 2006; 34:194-8.
47. Panzner P, Petrás M, Sýkora T, Lesná I. Double-blind, placebo-controlled evaluation of grass pollen specific immunotherapy with oral drops administered sublingually or supralingually. Respir Med 2008; 102:1296-304.
48. Passalacqua G, Albano M, Fregonese L et al. Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis. Lancet 1998; 351:629-32.
49. Passalacqua G, Albano M, Riccio A et al. Clinical and immunologic effects of a rush sublingual immunotherapy to Parietaria species: a double-blind, placebo-controlled trial. J Allergy Clin Immunol 1999; 104:964-8.
50. Passalacqua G, Pasquali M, Ariano R et al. Randomized double-blind controlled study with sublingual carbamylated allergoid immunotherapy in mild rhinitis due to mites. Allergy 2006; 61:849-54.
51. Pfaar O, Klimek L. Efficacy and safety of specific immunotherapy with a high-dose sublingual grass pollen preparation: a double-blind, placebo-controlled trial. Ann Allergy Asthma Immunol 2008; 100:256-63.
52. Pradalier A, Basset D, Claudel A et al. Sublingual-swallow immunotherapy (SLIT) with a standardized five-grass-pollen extract (drops and sublingual tablets) versus placebo in seasonal rhinitis. Allergy 1999; 54:819-28.
53. Purello-D'Ambrosio F, Gangemi S, Isola S et al. Sublingual immunotherapy: a double-blind, placebo-controlled trial with Parietaria judaica extract standardized in mass units in patients with rhinoconjunctivitis, asthma, or both. Allergy 1999; 54:968-73.
54. Rolinck-Werninghaus C, Wolf H, Liebke C et al. A prospective, randomized, double-blind, placebo-controlled multi-centre study on the efficacy and safety of sublingual immunotherapy (SLIT) in children with seasonal allergic rhinoconjunctivitis to grass pollen. Allergy 2004; 59:1285-93.
55. Röder E, Berger MY, Hop WC, Bernsen RM, de Groot H, Gerth van Wijk R. Sublingual immunotherapy with grass pollen is not effective in symptomatic youngsters in primary care. J Allergy Clin Immunol 2007; 119:892-8.
56. Sánchez Palacios A, Schamann F, García JA. Sublingual immunotherapy with cat epithelial extract. Personal experience. Allergol Immunopathol (Madrid) 2001; 29:60-5.
57. Smith H, White P, Annila I, Poole J, Andre C, Frew A. Randomized controlled trial of high-dose sublingual immunotherapy to treat seasonal allergic rhinitis. J Allergy Clin Immunol 2004; 114:831-7.
58. Torres-Lima M, Wilson D, Pitkin L et al. Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trial. Clin Exp Allergy 2002; 32:507-14.
59. Troise C, Voltolini S, Canessa A, Pecora S, Negrini AC. Sublingual immunotherapy in Parietaria pollen-induced rhinitis: a double-blind study. J Invest Allergol Clin Immunol 1995; 5:25-30.
60. Valovirta E, Jacobsen L, Ljørring C, Koivikko A, Savolainen J. Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children. Allergy 2006; 61:1177-83.
61. Vervloet D, Birnbaum J, Laurent P et al. Safety and efficacy of Juniperus ashei sublingual-swallow ultra-rush pollen immunotherapy in cypress rhinoconjunctivitis. A double-blind, placebo-controlled study. Int Arch Allergy Immunol 2007; 142:239-46.
62. Voltolini S, Modena P, Minale P et al. Sublingual immunotherapy in tree pollen allergy. Double-blind, placebo-controlled study with a biologically standardised extract of three pollens (alder, birch and hazel) administered by a rush schedule. Allergol Immunopathol (Madrid) 2001; 29:103-10.
63. Vourdas D, Syrigou E, Potamianou P et al. Double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization. Allergy 1998; 53:662-72.
64. Wahn U, Tabar A, Kuna P et al. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol 2009; 123:160-6.
65. Wüthrich B, Bucher Ch, Jörg W et al. Double-blind, placebo-controlled study with sublingual immunotherapy in children with seasonal allergic rhinitis to grass pollen. J Invest Allergol Clin Immunol 2003; 13:145-8.
66. Wilson DR, Lima MT, Durham SR. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 2005; 60:4-12.
67. Penagos M, Compalati E, Tarantini F et al. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. Ann Allergy Asthma Immunol 2006; 97:141-8.
68. Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev 2010; 12:CD002893.
69. Penagos M, Passalacqua G, Compalati E et al. Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest 2008; 133:599-609.
70. Compalati E, Passalacqua G, Bonini M, Canonica GW. The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-analysis. Allergy 2009; 64:1570-9.
71. Di Bona D, Plaia A, Scafidi V, Leto-Barone MS, Di Lorenzo G. Efficacy of sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a systematic review and meta-analysis. J Allergy Clin Immunol 2010; 126:558-66.
72. Bielory L. Ocular symptom reduction in patients with seasonal allergic rhinitis treated with the intranasal corticosteroid mometasone furoate. Ann Allergy Asthma Immunol 2008; 100:272-9.
73. Scadding GK, Keith PK. Fluticasone furoate nasal spray consistently and significantly improves both the nasal and ocular symptoms of seasonal allergic rhinitis: a review of the clinical data. Expert Opin Pharmacother 2008; 9:2707-15.
74. Baroody FM, Shenaq D, DeTineo M, Wang J, Naclerio RM. Fluticasone furoate nasal spray reduces the nasal-ocular reflex: a mechanism for the efficacy of topical steroids in controlling allergic eye symptoms. J Allergy Clin Immunol 2009; 123:1342-8.
75. Canonica GW, Fumagalli F, Guerra L et al. Levocetirizine in persistent allergic rhinitis: continuous or on-demand use? A pilot study. Curr Med Res Opin 2008; 24:2829-39.
76. Calderón MA, Penagos M, Durham SR. Sublingual immunotherapy for allergic rhinoconjunctivitis, allergic asthma, and prevention of allergic diseases. Clin Allergy Immunol 2008; 21:359-75.
77. Penagos M, Calderon MA, Durham SR. Dose effect of sublingual immunotherapy in the treatment of respiratory allergic diseases. Systematic review and meta-regression of randomized clinical trials, double-blind, placebo-controlled. J Allergy Clin Immunol 2008; 121:s125.
78. Calderón MA, Casale TB, Togias A, Bousquet J, Durham SR, Demoly P. Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond. J Allergy Clin Immunol 2011; 127:30-8.
79. Bousquet PJ, Calderon MA, Demoly P et al. The Consolidated Standards of Reporting Trials (CONSORT) Statement applied to allergen-specific immunotherapy with inhalant allergens: a Global Allergy and Asthma European Network (GA(2)LEN) article. J Allergy Clin Immunol 2011; 127:49-56.
80. Shea BJ, Grimshaw JM, Wells GA et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol 2007; 7:10.